https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39993 p < 5 x 10⁻⁸) in either cohort. Among the top 34 single-nucleotide polymorphisms (SNPs) (p < 1 x 10⁻⁶), two loci had concordant effects in both cohorts: ALOX15B (rs1804772) (MAF: 1%; p = 3.95 x 10⁻⁷) that influences arachidonic acid metabolism and thus platelet aggregation, and KALRN (rs570684) (MAF: 1%; p = 4.34 x 10⁻⁷) that has been previously associated with risk of ischemic stroke, atherosclerosis, and early-onset coronary artery disease. Conclusion: This represents the largest GWAS meta-analysis conducted to date associating SNPs to VTE in children and adolescents treated on childhood ALL protocols. Validation of these findings is needed and may then lead to patient stratification for VTE preventive interventions. As VTE hemostasis involves multiple pathways, a more powerful GWAS is needed to detect combination of variants associated with VTE.]]> Wed 20 Jul 2022 14:36:48 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27198 Wed 11 Apr 2018 14:24:41 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27195 Wed 11 Apr 2018 12:06:12 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27194 Wed 11 Apr 2018 10:34:47 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27197 Wed 11 Apr 2018 10:03:16 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29675 Wed 02 Mar 2022 14:26:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46701 P < 0.0001) and less pharmacologically attributable adverse events (Odds ratio 0.62; 95% confidence interval, 0.46–0.82; P = 0.0007). There was difference between DOACs and conventional VTE prophylaxis regarding mortality, PE, symptomatic deep vein thrombosis, or bleeding events. The results generally support the use of DOACs for VTE prophylaxis after nonelective lower limb fracture surgery, such after hip fracture. The results more strongly support the use of XaIs; however, more evidence is needed to fully assess DOACs' role in clinical practice. Level of Evidence: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.]]> Tue 29 Nov 2022 10:42:17 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10922 Tue 23 Oct 2018 16:22:24 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50863 Thu 17 Aug 2023 11:35:49 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20942 p = 0.020) and then further elevated after surgery (1 hour postoperative, 17.8 ± 2.0 U vs. preoperative, 13.8 ± 1.4 U, p = 0.008). Polytrauma patients were more hypercoagulable than nonpolytrauma at the preoperative sample time (17.7 ± 2.6 U vs. 10.7 ± 1.2 U, p = 0.040) and postoperative period (24.3 ± 3.4 U vs. 11.9 ± 1.4 U, p = 0.006). The OHP for patients undergoing open pelvic surgery (28.3 ± 3.0 U) was higher than both intramedullary nailing (16.2 ± 2.0 U) and percutaneous pelvic surgery (17.0 ± 1.7 U) on Day 5 (p < 0.05). Patients demonstrated a higher OHP than controls did at all time points, except at 6 weeks (patients, 10.8 ± 1.7 U vs. controls, 8.1 ± 0.5 U; p = 0.400). CONCLUSION: The OHP assay detected the hypercoagulable state following major orthopedic trauma and surgical intervention, which was present for 10 days postoperatively. The extent of hypercoagulability could be associated with polytrauma and the type of surgical intervention; however, further studies are needed to confirm this.]]> Sat 24 Mar 2018 08:06:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5047 Sat 24 Mar 2018 07:45:38 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22227 Sat 24 Mar 2018 07:17:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34877 Mon 23 Sep 2019 12:38:08 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46176 Mon 14 Nov 2022 08:57:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38488 Fri 08 Oct 2021 16:17:10 AEDT ]]>